Compare Citius Pharmaceuticals Inc (CTXR) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77. The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FLRN | |
|---|---|---|
Market Cap | $18.73M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $30.86 |
52-Week Low | $0.48 | $30.65 |
Enterprise Value | $14.95M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
FLRN trades at $30.76 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data. Recent dividend payments of $0.11 suggest stable income distribution, but fundamental analysis is limited without updated financial statements.
Outlook remains cautious due to bearish technical signals and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to assess profitability and growth. Primary risks include market volatility and reliance on future earnings reports for valuation clarity. Investors should await Q2 2026 results for deeper insight.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
